Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B

World Journal of Gastroenterology

Volumn 22, Issue 18, 2016, Pages 4529-4537

  Wang, Hong Juan ^a   Jiang, Yan Fang ^a,b   Wang, Xin Rui ^a   Zhang, Man Li ^a   Gao, Pu Jun ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; Chronic hepatitis B; Interleukin 12; Interleukin 38; Interleukin 6; Primary non response; Virological response

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CYTOKINE; HEPATITIS B(E) ANTIGEN; PROTEIN IL 38; TELBIVUDINE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BIOLOGICAL MARKER; IL-38 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; THYMIDINE; VIRUS DNA;

ADULT; ANALYTIC METHOD; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMETRIC BEAD ARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY TEST; MALE; PHYSICAL EXAMINATION; PREDICTION; PROTEIN BLOOD LEVEL; TH1 CELL; TH2 CELL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; DRUG ADMINISTRATION; HEPATITIS B, CHRONIC; ORAL DRUG ADMINISTRATION; SUSTAINED VIROLOGIC RESPONSE; TH1 TH2 BALANCE; TIME FACTOR; UPREGULATION; VIRUS LOAD; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; BIOMARKERS; CASE-CONTROL STUDIES; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKINS; MALE; SUSTAINED VIROLOGIC RESPONSE; TH1-TH2 BALANCE; THYMIDINE; TIME FACTORS; UP-REGULATION; VIRAL LOAD; YOUNG ADULT;

EID: 84970939221     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i18.4529     Document Type: Article

References (28)

1. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384: 2053-2063 [PMID: 24954675 DOI: 10.1016/S0140-6736(14)60220-8]
2. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]
3. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754-1764 [PMID: 22157327 DOI: 10.1136/gutjnl-2011-301073]
4. Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, Hao C, Niu J, Zhao P. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm 2010; 2010: 143026 [PMID: 21127728 DOI: 10.1155/2010/143026]
5. Bertino G, Ardiri AM, Calvagno GS, Bertino N, Ruggeri MI, Malaguarnera M, Malaguarnera G, Toro A, Di Carlo I. Telbivudine on-treatment HBsAg loss in naive HBeAg negative chronic hepatitis B: a case report and brief review of the literature. Clin Ter 2012; 163: e429-e434 [PMID: 23306758]
6. Wang K, Wu ZB, Ye YN, Liu J, Zhang GL, Su YJ, He HL, Zheng YB, Gao ZL. Plasma Interleukin-10: A Likely Predictive Marker for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Hepat Mon 2014; 14: e19370 [PMID: 25147572 DOI: 10.5812/ hepatmon.19370]
7. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124 [PMID: 17615358 DOI: 10.1126/science.1140485]
8. van de Veerdonk FL, Netea MG. New Insights in the Immunobiology of IL-1 Family Members. Front Immunol 2013; 4: 167 [PMID: 23847614 DOI: 10.3389/fimmu.2013.00167]
9. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013; 39: 1003-1018 [PMID: 24332029 DOI: 10.1016/j.immuni.2013.11.010]
10. Li C, Ji H, Cai Y, Ayana DA, Lv P, Liu M, Jiang Y. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. J Interferon Cytokine Res 2013; 33: 612-618 [PMID: 23697556 DOI: 10.1089/ jir.2013.0001]
11. Wang J, Cai Y, Ji H, Feng J, Ayana DA, Niu J, Jiang Y. Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B. J Interferon Cytokine Res 2012; 32: 248-253 [PMID: 22304300 DOI: 10.1089/jir.2011.0109]
12. Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, Pace AM, Hansen D, Schweighofer K, Mize NK, Ford JE. Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem 2001; 276: 20597-20602 [PMID: 11278614 DOI: 10.1074/jbc.M010095200]
13. van de Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG, Joosten LA, van der Meer JW, Hao R, Kalabokis V, Dinarello CA. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci USA 2012; 109: 3001-3005 [PMID: 22315422 DOI: 10.1073/pnas.1121534109]
14. Rudloff I, Godsell J, Nold-Petry CA, Harris J, Hoi A, Morand EF, Nold MF. Brief Report: Interleukin-38 Exerts Antiinflammatory Functions and Is Associated With Disease Activity in Systemic Lupus Erythematosus. Arthritis Rheumatol 2015; 67: 3219-3225 [PMID: 26314375 DOI: 10.1002/art.39328]
15. Ciccia F, Accardo-Palumbo A, Alessandro R, Alessandri C, Priori R, Guggino G, Raimondo S, Carubbi F, Valesini G, Giacomelli R, Rizzo A, Triolo G. Interleukin-36a axis is modulated in patients with primary Sjögren's syndrome. Clin Exp Immunol 2015; 181: 230-238 [PMID: 25902739 DOI: 10.1111/cei.12644]
16. Rahman P, Sun S, Peddle L, Snelgrove T, Melay W, Greenwood C, Gladman D. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006; 54: 2321-2325 [PMID: 16918024 DOI: 10.1002/art.21928]
17. Chou CT, Timms AE, Wei JC, Tsai WC, Wordsworth BP, Brown MA. Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Ann Rheum Dis 2006; 65: 1106-1109 [PMID: 16361275 DOI: 10.1136/ ard.2005.046847]
18. Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol 2013; 48: 999-1005 [PMID: 23338486 DOI: 10.1007/s00535-012-0742-5]
19. Wang GQ, Ding YP, Dong YH. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat 2013; 20 Suppl 1: 9-17 [PMID: 23458520 DOI: 10.1111/ jvh.12059]
20. Zheng Y, Huang Z, Chen X, Tian Y, Tang J, Zhang Y, Zhang X, Zhou J, Mao Q, Ni B, Wang Q, Wu Y. Effects of telbivudine treatment on the circulating CD4+ T-cell subpopulations in chronic hepatitis B patients. Mediators Inflamm 2012; 2012: 789859 [PMID: 22570512 DOI: 10.1155/2012/789859]
21. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
22. Mohamadnejad M, Montazeri G, Fazlollahi A, Zamani F, Nasiri J, Nobakht H, Forouzanfar MH, Abedian S, Tavangar SM, Mohamadkhani A, Ghoujeghi F, Estakhri A, Nouri N, Farzadi Z, Najjari A, Malekzadeh R. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 2006; 101: 2537-2545 [PMID: 17029616 DOI: 10.1111/j.1572-0241.2006.00788.x]
23. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829 [PMID: 10221919 DOI: 10.1126/science.284.5415.825]
24. Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Büning H, Rose-John S, Protzer U. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009; 50: 1773-1782 [PMID: 19937696 DOI: 10.1002/hep.23226]
25. Kuo TM, Hu CP, Chen YL, Hong MH, Jeng KS, Liang CC, Chen ML, Chang C. HBV replication is significantly reduced by IL-6. J Biomed Sci 2009; 16: 41 [PMID: 19374779 DOI: 10.1186/1423-0127-16-41]
26. Bouezzedine F, Fardel O, Gripon P. Interleukin 6 inhibits HBV entry through NTCP down regulation. Virology 2015; 481: 34-42 [PMID: 25765005 DOI: 10.1016/j.virol.2015.02.026]
27. Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 2010; 11: 789-806 [PMID: 20479986 DOI: 10.3390/ijms11030789]
28. Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S, Rosenberg W, Maini MK. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 2013; 9: e1003208 [PMID: 23516358 DOI: 10.1371/journal.ppat.1003208]